Literature DB >> 32406675

The Global Antibiotic Research and Development Partnership (GARDP) Not-for-Profit Model of Antibiotic Development.

Manica Balasegaram1, Laura J V Piddock1.   

Abstract

The Global Antibiotic Research and Development Partnership (GARDP) brings together public and private partners to accelerate the development and global availability of new antibiotics to treat the most challenging drug-resistant bacterial infections. Established in 2016, GARDP's recently launched strategy sets out its ambitious aim to deliver five new treatments by 2025, focusing on sexually transmitted infections, sepsis in newborns, and infections in hospitalized adults and children.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32406675     DOI： 10.1021/acsinfecdis.0c00101

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN： 2373-8227            Impact factor:   5.084


  6 in total

1.  Target-mediated competitive hybridization of hairpin probes for kanamycin detection based on exonuclease III cleavage and DNAzyme catalysis.

Authors:  Jiafeng Pan; Fang Deng; Lingwen Zeng; Zhi Liu; Junhua Chen
Journal:  Anal Bioanal Chem       Date:  2022-09-30       Impact factor: 4.478

2.  Analysis of Four New Enterococcus faecalis Phages and Modeling of a Hyaluronidase Catalytic Domain from Saphexavirus.

Authors:  Gustavo Di Lallo; Mattia Falconi; Federico Iacovelli; Domenico Frezza; Pietro D'Addabbo
Journal:  Phage (New Rochelle)       Date:  2021-09-17

Review 3.  A 'whole of United Nations approach' to tackle antimicrobial resistance? A mapping of the mandate and activities of international organisations.

Authors:  Didier Wernli; Stephan Harbarth; Nicolas Levrat; Didier Pittet
Journal:  BMJ Glob Health       Date:  2022-05

Review 4.  Towards the sustainable discovery and development of new antibiotics.

Authors:  Marcus Miethke; Marco Pieroni; Tilmann Weber; Mark Brönstrup; Peter Hammann; Ludovic Halby; Paola B Arimondo; Philippe Glaser; Bertrand Aigle; Helge B Bode; Rui Moreira; Yanyan Li; Andriy Luzhetskyy; Marnix H Medema; Jean-Luc Pernodet; Marc Stadler; José Rubén Tormo; Olga Genilloud; Andrew W Truman; Kira J Weissman; Eriko Takano; Stefano Sabatini; Evi Stegmann; Heike Brötz-Oesterhelt; Wolfgang Wohlleben; Myriam Seemann; Martin Empting; Anna K H Hirsch; Brigitta Loretz; Claus-Michael Lehr; Alexander Titz; Jennifer Herrmann; Timo Jaeger; Silke Alt; Thomas Hesterkamp; Mathias Winterhalter; Andrea Schiefer; Kenneth Pfarr; Achim Hoerauf; Heather Graz; Michael Graz; Mika Lindvall; Savithri Ramurthy; Anders Karlén; Maarten van Dongen; Hrvoje Petkovic; Andreas Keller; Frédéric Peyrane; Stefano Donadio; Laurent Fraisse; Laura J V Piddock; Ian H Gilbert; Heinz E Moser; Rolf Müller
Journal:  Nat Rev Chem       Date:  2021-08-19       Impact factor: 34.571

5.  A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution.

Authors:  Laura J V Piddock; Jean-Pierre Paccaud; Seamus O'Brien; Michelle Childs; Rohit Malpani; Manica Balasegaram
Journal:  Clin Infect Dis       Date:  2022-05-30       Impact factor: 20.999

6.  There is no market for new antibiotics: this allows an open approach to research and development.

Authors:  Dana M Klug; Fahima I M Idiris; Mark A T Blaskovich; Frank von Delft; Christopher G Dowson; Claas Kirchhelle; Adam P Roberts; Andrew C Singer; Matthew H Todd
Journal:  Wellcome Open Res       Date:  2021-06-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.